Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical testing and is currently being evaluated in a Phase 1/2-3 clinical study.

In the study, the safety, toxicology and pharmacokinetics of IB1001 were evaluated in animal models and compared to commercially available Factor IX products. Results showed that IB1001 has an excellent safety profile in animal models and a similar pharmacokinetic profile when compared to currently available Factor IX products.

"These results and the progress that we have made in advancing our protein manufacturing technology have facilitated the advancement of IB1001 into a Phase 1/2-3 clinical program," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia around the world. We expect to move IB1001 into a pivotal trial and look forward to updating you on all developments related to this program."

About IB1001

IB1001 is an intravenous recombinant Factor IX product for the acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced with Inspiration's proprietary recombinant protein manufacturing technology, which significantly increases cell-line productivity.

About Hemophilia

Hemophilia is a lifelong, inherited bleeding disorder cause
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
(Date:7/27/2015)... ... 27, 2015 , ... Brady (NYSE:BRC), a global ... 3 Ways to GHS Labels . This video provides useful information on how ... by effectively labeling chemical containers. , “With the fourth and final deadline for ...
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Brady Releases “3 Roads to GHS Labels” Video 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... , July 28 VIASPACE Inc. (OTC Bulletin ... as a low-carbon, renewable biomass crop, reported that Chief Executive ... the Third Annual World Congress of Industrial Biotechnology held in ... more than 500 business executives, industry leaders, technical experts, government ...
... Ind. - Researchers have discovered mechanisms critical to interactions ... a thermonuclear fusion reactor, part of work aimed at ... the reactors. Fusion powers the stars and could ... fusion power plant would produce 10 times more energy ...
... PHILADELPHIA , July 27 All signs point to accelerated ... is driving an explosion of demand for services, central government policy continues ... 1-5 PM on Wednesday, September 8 , executives and managers ... "China Business Toolbox." , , ...
Cached Biology Technology:VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 2VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 3VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 4Findings show promise for nuclear fusion test reactors 2Findings show promise for nuclear fusion test reactors 3Orchestrall Sponsors 'China Business Toolbox': Brings Focus to the 'How and When' of China Market Access 2Orchestrall Sponsors 'China Business Toolbox': Brings Focus to the 'How and When' of China Market Access 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... greenhouses have played a vital role in China,s ... design are allowing growers to produce more varieties ... a recently published report Chinese scientists called solar ... growing horticultural crops in China." The team of ...
... Mich. (March 17, 2011) In a ... so-called "orphan" nuclear receptor TR4, Van Andel Research Institute ... more direct role than was previously known in certain ... of the central nervous system. Scientists had previously ...
... This release is available in German ... herbivore attack. To defend themselves, they have developed sophisticated ... as thale cress ( Arabidopsis thaliana ), produce glucosinolates ... know many different kinds of these molecules; they have ...
Cached Biology News:Solar greenhouses: China's winning solution to global energy crisis 2Study indicates vitamin A plays key role in the human body 2Production of mustard oils: On the origin of an enzyme 2Production of mustard oils: On the origin of an enzyme 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
... Single Cell Whole Genome Amplification Kit ... random fragmentation of genomic DNA and ... to PCR-amplifiable library molecules flanked by ... by PCR amplification of the library ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
Biology Products: